Patents for A61P 35 - Antineoplastic agents (221,099)
09/2006
09/05/2006US7102003 4-(1-(3-Fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-ol; inhibiting tyrosine kinase activity of growth factor receptors; antiproliferative agents, anticancer agents
09/05/2006US7102002 Pyrrolotriazine kinase inhibitors
09/05/2006US7102001 Process for preparing pyrrolotriazine
09/05/2006US7102000 Heterocyclic amide derivatives for the treatment of diabetes and other diseases
09/05/2006US7101991 antisense hsp27 oligonucleotides or RNAi nucleotide inhibitors
09/05/2006US7101979 Antibodies to antiangiogenic compositions and methods
09/05/2006US7101977 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
09/05/2006US7101974 Tumor necrosis factor ptotein; for use in the treatment of rheumatic diseases and arthritis
09/05/2006US7101972 With binding specificity for target nucleotides containing one or GNN triplets; regulating gene expression
09/05/2006US7101911 Bis(substituted propynyl)-substituted benzenes, pyridines, pyrimidines, pyrazines, pyridines, furans and pyrroles; e.g., 3,5-bis-(3-(4-aminomethylbenzylaminocarbonyloxy)prop-1-ynyl)--1 -hydroxymethylbenzene
09/05/2006US7101908 Nontoxic treatment for infections from cytomegalovirus
09/05/2006US7101897 Farnesyl transferase inhibitors
09/05/2006US7101891 Compounds and pharmaceutical compositions for inhibiting MRP1
09/05/2006US7101884 Tyrosine kinase inhibitors
09/05/2006US7101876 Substituted benzoxazines as integrin antagonists
09/05/2006US7101868 A 2-(((4-fluorophenyl)methyl)amino)-3-pyridinecarboxamide derivatives for treating cancer, angiogenesis, tumor
09/05/2006US7101865 24-sulfoximine vitamin D3 compounds
09/05/2006US7101864 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells
09/05/2006US7101856 Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
09/05/2006US7101850 WISP polypeptides and nucleic acids encoding same
09/05/2006US7101711 Activating a T gamma 9 delta 2 lymphocyte at a minimum activation concentration of below 100 nM, in vitro by contacting with a 3,4-epoxy-3-methyl-1-butyl diphosphate substituted with a biomolecule
09/05/2006US7101705 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
09/05/2006US7101702 Fermentative preparation process for and crystal forms of cytostatics
09/05/2006US7101568 Biodegradation organophosphorus polymer; administering to tumor in situ
09/05/2006US7101560 Combination vaccine for administration to adolescents
09/05/2006US7101557 Promoting coagulation in prothrombotic blood vessels, treating a vascularized tumor with a coagulation-deficient tissue factor compound
09/05/2006US7101550 Agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response
09/05/2006US7101548 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
09/05/2006CA2393640C Pyrrolo[2,3-d]pyrimidine compounds
09/05/2006CA2206567C Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
08/2006
08/31/2006WO2006091972A2 Dimeric iap inhibitors
08/31/2006WO2006091963A1 Tetrahydroindolone and tetrahydroindazolone derivatives
08/31/2006WO2006091693A2 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
08/31/2006WO2006091671A1 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors
08/31/2006WO2006091669A1 Anti-cancer and anti-microbial oxazolidinones and analogues
08/31/2006WO2006091450A1 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
08/31/2006WO2006091326A1 Anti-prl-3 antibodies and methods of use thereof
08/31/2006WO2006091112A1 Compositions for the delivery of rna interference molecules and methods for their use
08/31/2006WO2006091009A1 Pharmaceutical composition for the treatment of cancer comprising lmh-ra complex
08/31/2006WO2006090932A1 Surrogate marker for sulfonamide compound
08/31/2006WO2006090931A1 Novel concomitant use of sulfonamide compound with anti-cancer agent
08/31/2006WO2006090930A1 Novel combinational use of sulfonamide compound
08/31/2006WO2006090928A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor
08/31/2006WO2006090921A1 Inhibitory effect of sulfonamide compound on lymphocyte activation
08/31/2006WO2006090906A1 NOVEL METHOD FOR OVERCOMING RNAi-RESISTANT STRAIN OF VIRUS
08/31/2006WO2006090900A1 Preventives/remedies for cancer
08/31/2006WO2006090853A1 Nitrogenous heterocyclic compound and medicinal use thereof
08/31/2006WO2006090813A1 Element retained in blood showing degradability selectively in tumor tissue
08/31/2006WO2006090750A1 ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
08/31/2006WO2006090743A1 1-(2h)-isoquinolone derivative
08/31/2006WO2006090717A1 Quinazoline derivative having tyrosine kinase inhibitory activity
08/31/2006WO2006090698A1 Kinase inhibitor and use thereof
08/31/2006WO2006090494A1 Anticancer agent
08/31/2006WO2006090413A1 Novel crystalline form of gefitinib and a process for its preparation
08/31/2006WO2006090261A1 Bicyclic heteroaromatic derivatives useful as anticancer agents
08/31/2006WO2006090163A1 Quinazoline derivatives as tyrosine kinase inhibitors
08/31/2006WO2006090150A1 Pharmaceutical composition comprising amorphous rosiglitazone
08/31/2006WO2006090129A2 Bicalutamide for delivering increasing steady state plasma levels
08/31/2006WO2006090094A1 Pyrimidothiophene compounds for use as hsp90 inhibitors
08/31/2006WO2006090052A1 Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing same and use thereof
08/31/2006WO2006089874A1 Benzo[2,3]azepino[4,5-b]indol-6-ones
08/31/2006WO2006089803A1 Method and composition to inhibit infections with helicobacter pylori by intake of procyanidins from type b and c
08/31/2006WO2006089781A1 Pharmaceutical combination of bcr-abl and raf inhibitors
08/31/2006WO2006089549A1 Ykl-40 monoclonal antibodies
08/31/2006WO2006089537A1 Method for production of a preparation of a solid dmso-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies
08/31/2006WO2006089455A1 Targeting anti-tumour fusion protein containing adenovirus e4orf4 protein
08/31/2006WO2006089406A1 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
08/31/2006WO2006074914A3 Human rna helicase and therapeutic uses thereof
08/31/2006WO2006074223A3 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
08/31/2006WO2006066957A3 Sulfonamido-macrocycles as tie2 inhibitors
08/31/2006WO2006064121A3 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations
08/31/2006WO2006062984A3 Inhibitors of protein kinases
08/31/2006WO2006056696A3 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
08/31/2006WO2006056399A3 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
08/31/2006WO2006048862A3 The use of a protease or a protease inhibitor for the manufacture of medicaments
08/31/2006WO2006044933B1 Compositions and methods for disruption of brca2-rad51 interaction
08/31/2006WO2006034278A3 Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
08/31/2006WO2006029176A3 Cancer-testis antigens
08/31/2006WO2005120577A3 Derivatives of chemotherapeutic agents with a formaldehyde releasing moeity
08/31/2006WO2005065717A3 Liquid formulations of antibody conjugates
08/31/2006WO2005035507A3 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
08/31/2006US20060194883 Mmp expression inhibitor
08/31/2006US20060194872 Diamine derivative, production process therefor and antioxidant
08/31/2006US20060194863 e.g. [(4-Morpholinophenylamino)-methylene]-1,3-dihydro-indol-2-one;tyrosine kinase signal transduction modulators; antiproliferative agents; vision defects, atherosclerosis, restenosis, metabolic disorders, autoimmune diseases
08/31/2006US20060194850 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease
08/31/2006US20060194848 Substituted amine derivatives and methods of use
08/31/2006US20060194843 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide
08/31/2006US20060194836 Novel compounds having 4-pyridylalkylthio group as substituent
08/31/2006US20060194818 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
08/31/2006US20060194816 Benzofuran derivatives useful for treating hyper-proliferative disorders
08/31/2006US20060194793 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
08/31/2006US20060194792 1-Cyclic carbonyl-4-(4-quinoline-)-1,4-diazepine or 1-cyclic carbonyl-4-[4-(1H-quinolin-2-{thio}one)-1,4-diazepinone derivatives; retinopathy, adult respiratory distress syndrome, asthma, osteoarthritis, glomerulonephritis, psoriasis, rheumatoid arthritis, and toxic shock syndrome treatment
08/31/2006US20060194774 Increased activity for the treatment of carcinomas and HIV diseases, melanoma, neuroectodermal tumor, sarcoma
08/31/2006US20060194755 Compositions and methods for regulating an immune response in a subject
08/31/2006US20060194745 Compounds and methods for inhibiting selectin-mediated function
08/31/2006US20060194744 Illudin analogs useful as antitumor agents
08/31/2006US20060194736 Polypeptide for the treatment of cancer and a method for preparation thereof
08/31/2006US20060194735 Extending the shelf life of Therapeutic protein X; nucleic acids and vectors containing them; kits; treating, preventing, or ameliorating diseases, disorders or conditions
08/31/2006US20060194731 Using tumor antigens to elicit immune response targeted to cancer cells; immunotherapy
08/31/2006US20060194304 Kit comprising sodium chloride, potassium chloride, guanidinium chloride, sodium perchlorate or other chaotropic salt; and a nonionic detergent of Triton, NP40, Tween, or Syperonic, or MOPS buffer; endotoxin-free; purification, centrifuging, chromatography, filtration; gene therapy